The United States bade pharma company Moderna claimed that its vaccine against the Covid-19 disease have displayed “robust” immune response in all 45 patients in its early stage human trial. This was revealed in a newly released data that was published on Tuesday in the peer-reviewed New England Journal of Medicine.
This resulted in a spike in the shares of the company with an almost 16 per cent spike in after-hours trading on Tuesday after the publication of the news on the vaccine.
According to reports, neutralizing antibodies were produced in all 45 patients who were part of the human trials. According to scientists, such antibodies are critical for building up immunity inside human bodies against the disease. The report also provided some more promising data about the vaccine which can make it viable to give some protection to humans against thee disease.
A 25, 100 or 250 microgram dose was administered to each participant in the trial and 15 people were included in each dose group. Two doses of the potential vaccine were administered to the participants.
Moderna said that a “robust” immune response in all participants in all dose cohorts as elicited by the vaccine after two vaccinations. The levels of neutralizing antibodies that were developed in the bodies of patients in the high dose group were found to be four time higher than those in the bodies of patients who had recovered from Covi-19, the company said.
“These Phase 1 data demonstrate that vaccination with mRNA-1273 elicits a robust immune response across all dose levels and clearly support the choice of 100 µg in a prime and boost regimen as the optimal dose for the Phase 3 study,” Moderna’s chief medical officer, Tal Zaks, said in a statement. “We look forward to beginning our Phase 3 study of mRNA-1273 this month to demonstrate our vaccine’s ability to significantly reduce the risk of COVID-19 disease.”
Preliminary information from its early stage trial was released by the company in May this year, but that did not have all of its data and it was not per reviewed then.
While the side effect of the vaccine candidate was more or less well tolerated, Moderna said that mild or moderate symptoms such as fatigue, muscle aches or pain at the injection site were reported by more than half of the participants.
Moderna said that it is currently examining the durability of immune responses created by the vaccine and the company will follow the participants for a year after the second vaccination.
According to data compiled by Johns Hopkins University, there are a number of other firms and bodies that are currently working on developing a vaccine for Covid-19 hich has already infected more than 13 million people and resulted in death of at least 573,200 of them across the globe.
According to the World Health Organization, there are currently more than 100 vaccines under development globally.
Genetic material called messenger RNA, or mRNA forms the basis of Moderna’s experimental vaccine. The mRNA is a genetic code that tells cells what to build — in this case, an antigen that may induce an immune response to the virus. This was the forts vaccine candidate in the world that entered into the phase 1 human trial in March.
(Adapted from CNBC.com)